Efficacy of low dose naltrexone for patients that suffer from comorbid depressive illness (Abstract)

The LDN Conference 2021: 4th - 6th June 2021

Up to 29 CME Credits Available + Sponsor, Exhibitor and Advertiser Opportunities.  [More Details]

Efficacy of low dose naltrexone for patients that suffer from comorbid depressive illness

The 15th Pacific Rim College of Psychiatrists Scientific Meeting
October 2012
https://onlinelibrary.wiley.com/doi/pdf/10.1111/appy.12002

This study is a retrospective chart review meant to investigate the efficacy of low dose naltrexone (LDN) for the treatment of patients with co-morbid depression and collagen disease. At week 4, 80% of patients experienced a certain degree of improvement with LDN.